诺和诺德(Novo Nordisk)最新研发的减肥药CagriSema在临床试验中表现不及预期,导致公司市值蒸发高达1000亿美元。 CagriSema平均帮助患者减重22.7%,低于公司预期的25%。此外,仅57%的患者能够接受最高剂量,表明该药可能存在较难忍受的副作用。 这一打击紧随诺和诺德9月份宣布其实验性减肥药片monlunabant未能达到市场预期之后。诺和诺德股价周五暴跌超20%,较...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.